Journey Medical Corp

Listed Company

DERMCIK 0001867066NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$61.86M

Net Income

$-11.43M

Total Assets

$94.59M

Equity

$31.85M

Shares Out

11.56M

Op. Cash Flow

$-12.44M

Business

Journey Medical Corp is a commercial-stage pharmaceutical company that sells and markets FDA-approved prescription drugs for dermatological conditions. It markets eight FDA-approved dermatology products—including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox and Luxamend—and acquires or licenses additional products. Core activities include commercialization via a field sales organization, product acquisitions and in-licensing, business development, and out-licensing. It generates revenue primarily in the U.S. through specialty pharmacies, independent wholesalers, distributors and its field sales force, and pursues targeted international licensing.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Product revenue, net	61	55	60	71	63
Other revenue	619,000	1	20	3	—
Total revenue	62	56	79	74	63
Cost of goods sold - (excluding amortization of acquired intangible assets)	21	21	23	31	32
Amortization of acquired intangible assets	4	3	4	—	—
Research and development	480,000	10	8	11	3
Selling, general and administrative	44	40	44	59	40
Loss recovery	—	−5	—	—	—
Total operating expenses	70	70	81	101	98
Loss from operations	−8	−14	−2	−28	−35
Interest income	−589,000	−757,000	−322,000	−60,000	−2,000
Interest expense	4	3	2	—	—
Gain on extinguishment of debt	—	−1	—	—	—
Foreign exchange transaction losses	90,000	116,000	183,000	89,000	—
Total other expense	3	934,000	2	2	7
Loss before income taxes	−11	−15	−4	−30	−42
Income tax expense	60,000	61,000	221,000	63,000	2
Net loss	−11	−15	−4	−30	−44
Basic (In dollars per share)	−0.47	−0.72	−0.21	−1.69	−4.32
Diluted (In dollars per share)	−0.47	−0.72	−0.21	−1.69	−4.32
Basic (In shares)	24	20	18	18	10
Diluted (In shares)	24	20	18	18	10

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	24	20	27	32	49
Accounts receivable, net of reserves	30	10	15	28	23
Inventory	10	14	10	14	10
Prepaid expenses and other current assets	3	3	4	3	2
Total current assets	67	48	56	78	84
Intangible assets, net	28	32	20	27	13
Operating lease right-of-use asset, net	111,000	199,000	101,000	189,000	89,000
Total assets	95	80	77	105	97
Accounts payable	9	16	18	37	23
Due to related party	455,000	528,000	195,000	413,000	—
Accrued expenses	28	17	20	19	23
Accrued interest	398,000	404,000	22,000	160,000	—
Income taxes payable	70,000	60,000	53,000	35,000	8,000
Installment payments - licenses, short-term	—	625,000	3	2	5
Operating lease liability, short-term	101,000	83,000	99,000	83,000	98,000
Total current liabilities	37	35	42	67	52
Term loan, net of discount	25	25	15	20	—
Operating lease liability, long-term	18,000	118,000	9,000	108,000	—
Total liabilities	63	60	56	88	55
Commitments and contingencies (Note 13)	—	—	—	—	—
Additional paid-in capital	130	107	93	85	81
Accumulated deficit	−98	−87	−72	−69	−39
Total stockholders' equity	32	20	20	17	42
Total liabilities and stockholders' equity	95	80	77	105	97

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−11	−15	−4	−30	−44
Bad debt (recovery) expense	−211,000	516,000	435,000	284,000	48,000
Amortization of debt discount	466,000	307,000	356,000	63,000	3
Amortization of operating lease right-of-use assets	88,000	91,000	88,000	88,000	86,000
Share-based compensation	6	6	3	4	2
Accounts receivable	−19	4	13	−5	768,000
Inventory	5	−4	4	2	−8
Prepaid expenses and other current assets	−164,000	376,000	−279,000	−871,000	−774,000
Other assets	—	6,000	—	55,000	−144,000
Accounts payable	−7	−2	−18	14	20
Related party expenses	−73,000	333,000	−218,000	−228,000	2
Accrued expenses	10	−3	962,000	−4	1
Accrued interest	−6,000	382,000	−138,000	160,000	—
Income tax payable	10,000	7,000	18,000	27,000	−91,000
Lease liabilities	−82,000	−96,000	−83,000	−95,000	−84,000
Net cash (used in) operating activities	−12	−9	5	−14	−2
Acquired intangible assets	—	−15	−5	−20	—
Net cash (used in) investing activities	—	−15	−5	−20	−10
Proceeds from the exercise of stock options	350,000	207,000	121,000	142,000	7,000
Proceeds from issuance of common stock, ATM offering, net of issuance costs	16	8	4	—	33
Issuance of common stock under ESPP	217,000	209,000	—	—	—
Proceeds from term-loan	—	10	15	20	—
Payment of debt issuance costs	−75,000	−50,000	−471,000	—	—
Payment of license installment note payable	−625,000	−1	−1	−5	−5
Net cash provided by financing activities	16	17	−5	16	53
Net change in cash	4	−7	−5	−17	41
Cash paid for interest	3	2	1	993,000	—
Cash paid for income taxes	50,000	125,000	181,000	168,000	158,000
ROU assets obtained in exchange for lease liabilities	—	188,000	188,000	188,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro